ABSTRACT
The pivotal role that multiple pancreatic and gut hormones play in the maintenance of glucose homeostasis has become increasingly apparent over the past several years (1,2). We know today that in patients with diabetes, hyperglycemia results not only from factors beyond absolute or relative insulin deficiency and insulin resistance, but also from abnormalities in secretion and action of a number of hormones including the a-cell hormone glucagon, the incretin glucagon-like-peptide-1, and the b-cell hormone amylin (1,2). This chapter focuses on the hormone amylin and the therapeutic use of the amylin analog pramlintide in the management of insulin-using patients with type 2 diabetes.
